All In MedTech

Device Trial Radar · NCT07856797

A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds

A Prospective, Open-Label, Multicenter, Post-Market Clinical Follow-Up Study to Confirm the Long-term Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

163

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Aug 2027

Study completion Feb 2029

Sponsor

Lead sponsor
Merz North America, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm the long-term safety, effectiveness, and degradation profile of RADIESSE® Injectable Implant for the correction of moderate to severe nasolabial folds (NLFs) in Chinese adults. Eligible participants will receive treatment with RADIESSE® Injectable Implant in both NLFs and may receive an optional touch-up treatment at Month 1 at investigator's discretion. Participants will be followed for up to 24 months after last treatment.

Conditions

  • Nasolabial Folds

Interventions

  • Subdermal ImplantDevice

    Participants will receive treatment with RADIESSE® Injectable Implant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving at Least a 1-point Improvement in Both NLFs From Baseline to Month 6 after Last Treatment on the Wrinkle Severity Rating Scale (WSRS), as Assessed Live by the Treating InvestigatorTime frame: At Month 6 after last treatment

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Merz Investigative Site

    Beijing, China · Recruiting

  • Merz Investigative Site

    Changde, China · Recruiting

  • Merz Investigative Site

    Chengdu, China · Recruiting

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.